[Reconstructive phalloplasty]. / Falloplastica ricostruttiva.

We examine some surgical techniques proposed for phallic reconstruction. Together with cutaneous flaps, muscle-cutaneous flaps, who present the advantage of more constant results, are progressively listed. We also present a personal technique of phallic reconstruction with double prosthesis: one external, vascular and one internal, for the erection.

[Topical treatment of erectile dysfunction. Possibilities and perspectives]. / Il trattamento topico dei deficit erettili. Possibilità e prospettive.

In this work the Authors speak about topical treatment in diagnosis and therapy of erectile deficit with prostaglandin, papaverine, phentolamine, V.I.P., nitroglycerine, minoxidil and others. These drugs must have some chemicophysical trait to be adsorbed by the skin. The concepts of microangiotettonic, microangiopathy, microangiokinesis are very important in erectile dysfunctions. For the future there are perspectives to use microvasculokinesic and antiperossidasic complex, alone or in association with intravenous pharmacotherapy.

[Adjuvant chemotherapy in infiltrating bladder carcinoma. Long-term results]. / La chemioterapia adiuvante nel carcinoma vescicale infiltrante. Risultati a distanza.

The authors present the long-term of adjuvant chemotherapy using M-VEC scheme (Mtx 20 mg/mq; vinblastine 0.1 mg/kg; CDDP 40 mg/mq; epirubicin 30 mg/mq each 21 day for six cycles) effected in 28 patients (21 males and 7 women with average age of 67) undergone radical cystectomy for invasive bladder carcinoma p G2-3 T-4 N + M0. Total survival after 5 years was 28.6% while disease-free survival is 18.8%; in 71.3% there are been clinical progression and the mortality to 5 years was 62%.

[Adjuvant chemo-immunotherapy with VBL + INF in renal carcinoma. Long-term results]. / Chemioimmunoterapia adiuvante con VBL + INF nel Ca Renale. Risultati a distanza.

Authors show results of adjuvant chemoimmunotherapeutic approach (0, 10 mg/kg Vinblastine every three weeks plus INF - alpha 2a - and INF - alpha 2b in a dose of 3 x 10(6) U.I. three times a week) adopted after radical nephrectomy in 45 patients with renal carcinoma (p. T3/4. NO.MO; pT3/4. N+/O. M+/O). The treatment may be summed up: 1# to effect a regression of metastasis that is not possible surgically to remove either because of its location or extent; 2) to limit micrometastatic diffusion in patients with N+. 3) It is important to perform this treatment in stage T3 N0M0 where clinical progression is (21.1%) in our group.

[Treatment of prostatic pathology with local hyperthermia. Analysis of the results of a study on 60 patients]. / Il trattamento delle patologie prostatiche con l'ipertermia locale. Analisi dei risultati da uno studio su 60 pazienti.

The authors report the results of the hyperthermic treatment employed from January 1989 to April 1991 in 60 patients with BPH, PR and NP. Analysis of the results shows a determinant role for prostatitis (RC: 73.91%); the results for BPH are equally valid (RC: 56.25%). The authors used the same treatment for BPH with initially obstructive urinary symptomatology.

[Percutaneous use of vasoactive drugs in the diagnosis and treatment of erectile impotence]. / Impiego percutaneo di farmaci vasoattivi nella diagnosi e nella terapia dell'impotenza erettile.

The Authors report their experience of topical and intracavernous treatment with papaverine and phentolamine in patients with erectile dysfunction from May 1988 to March 1992. Topical application of drug cream proves efficacious both alone or combined with intracavernous injection with PGE1. Topical treatment besides may be carried out without systemic or local complications.

[Transitional cell carcinoma of the urethra in patients after cystectomy for bladder carcinoma]. / Il carcinoma a cellule transizionali dell'uretra nei pazienti cistectomizzati per ca. vescicale.

Transitional cell carcinoma of the urethra in men after radical cystectomy for bladder carcinoma have an incidence which varies from 4 to 18%. The Authors present their experience of 6 cases (6/196; 3.06%) analysing the characteristics of the urethral neoplasm and confirming the systematic cystourethrectomy when there is a urethra prostatic and bladder neck infiltration or when there is a urethral ca in situ. It also underlines the role of the clinical, radiological, cytological and urethro-endoscopical follow-up in patients who have undergone a cystoprostatovesciculectomy.

[Male-female transsexualization with glandular preservation]. / Transessualizzazione andro-ginoica con conservazione del glande.

The choice of the tissue to build up the neovagina is an important step in the surgical treatment of transsexualism. Both the penile skin and an intestinal segment are possible solutions to the problem. However intestinal segments have some defects like continuous secretions and painful intercourse. For these reasons the authors prefer the penile skin with the neuro-vascular bundle preserved. One hundred cases of this surgery are presented.

[Follow-up of surgically treated transsexuals: what has changed?]. / Follow up dei transessuali operati: cosa è cambiato?

The surgery for both male and female transsexuals causes great difference in the behavior of operated patients. Then it is very important to analyze the variations of three parameters before and after operation: 1) the presence and the character of sexual feeling and the modality of sexual intercourse; 2) possibility of orgasm; 3) working behavior. The authors present the results of their study on 16 male transsexuals and 4 female transsexuals.

[Adjuvant M-VEC in advanced urotheliomas of the bladder]. / M-VEC adiuvante negli uroteliomi avanzati della vescica.

The therapeutic efficacy of chemotherapy in bladder's carcinoma is today supported by many statistical reports; the response rates are ranging from 35% to 45%. Results of the treatment with adjuvant chemotherapy (M-VEC in 22 patients with or without metastatic tumor are presented. Favourable objective responses were seen in 25% of the patients. The conclusion is drawn that this therapy is very useful in the treatment of metastatic diseases, but it can be used also in non-metastatic (M0) patients to prevent the growth of micrometastasis.